Pancreatic cancer — frontier options in Kansas

17 open options

TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
TRIALPHASE1RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Metarrestin — 2 sites
EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
TRIALPHASE1 / PHASE2RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RMC-6236 · mFOLFOX6 regimen · bevacizumab — 32 sites
TRIALPHASE1 / PHASE2RECRUITING
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Onvansertib · NALIRIFOX — 1 site
TRIALPHASE2RECRUITING
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
TCMCB07 · Placebo — 26 sites
TRIALPHASE2RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Capecitabine · Temozolomide — 448 sites
TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
TRIALPHASE2RECRUITING
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Relacorilant · Nab-paclitaxel · Gemcitabine — 16 sites
TRIALPHASE1 / PHASE2RECRUITING
Lead-212 PSV359 Therapy for Patients With Solid Tumors
[203Pb]Pb-PSV359 · [212Pb]Pb-PSV359 — 11 sites
TRIALPHASE1 / PHASE2RECRUITING
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
FMC-376 — 26 sites
TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Computed Tomography — 44 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.